Financial Assistance
Newsletter Sign-up
Need Appointment
Contact Us
About Us

Rush University
For Physicians
For Rush Employees
For Students
Bill Payment Center
Rotate
<< Previous | New Search | Return to Search Results | Next >>

Christopher G. Goetz, MD

Christopher G. Goetz, MD
Appointment Request

Or call
(888) 352-RUSH for help arranging an appointment.
Specialty:
  • Neurology
Board Certification:
  • Neurology
Faculty Rank: Professor
Medical or Graduate Education: Rush Medical College
Residency: Michael Reese Hospital and Medical Center - Neurology
  Rush University Medical Center - Neurology
Clinical Expertise:
  • Corticobasal degeneration
  • Dystonia
  • Hemifacial spasm
  • Huntington's disease
  • Movement disorders
  • Movement disorders, fragile X-associated
  • Multiple system atrophy
  • Myoclonus
  • Parkinsonism
  • Parkinson's disease
  • Progressive supranuclear palsy
  • Restless leg syndrome
  • Stiff-person syndrome
  • Tics
  • Tourette syndrome
  • Tremor
  • Wilson's disease
  • Writer's cramp
Research Interests:
  • Parkinson disease
  • Tourette's syndrome
  • Huntington disease
  • Dystonia
  • Neuropsychiatric features and genetics of Parkinson disease
  • Clinical trials in Parkinson disease
  • Pharmacological studies of movement disorders
  • Cognition in Parkinson disease
Languages Spoken:
  • French
Google Map

Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to PubMed.gov). Listings go back five years.

  1. Task force report: Scales for screening and evaluating tremor: Critique and recommendations.
    Elble R, Bain P, João Forjaz M, Haubenberger D, Testa C, Goetz CG, Leentjens AF, Martinez-Martin P, Pavy-Le Traon A, Post B, Sampaio C, Stebbins GT, Weintraub D, Schrag A
    Mov. Disord.
    2013 Sep 3
  2. Defining optimal cutoff scores for cognitive impairment using Movement Disorder Society Task Force criteria for mild cognitive impairment in Parkinson's disease.
    Goldman JG, Holden S, Bernard B, Ouyang B, Goetz CG, Stebbins GT
    Mov. Disord.
    2013 Oct 9
  3. Movement Disorder Society Unified Parkinson Disease Rating Scale experiences in daily living: Longitudinal changes and correlation with other assessments.
    Lang AE, Eberly S, Goetz CG, Stebbins G, Oakes D, Marek K, Ravina B, Tanner CM, Shoulson I,
    Mov. Disord.
    2013 Oct 9
  4. Diffusion tensor imaging of Parkinson's disease, atypical parkinsonism, and essential tremor.
    Prodoehl J, Li H, Planetta PJ, Goetz CG, Shannon KM, Tangonan R, Comella CL, Simuni T, Zhou XJ, Leurgans S, Corcos DM, Vaillancourt DE.
    Mov Disord. 2013
    2013 May 14. doi: 10.1002/mds.25491. [Epub ahead of print]
  5. The Parkinson's disease multidisciplinary package.
    Goetz CG.
    Mov Disord. 2013
    2013 Mar 11. doi: 10.1002/mds.25414. [Epub ahead of print] No abstract available.
  6. Which dyskinesia scale best detects treatment response?
    Goetz CG, Stebbins GT, Chung KA, Hauser RA, Miyasaki JM, Nicholas AP, Poewe W, Seppi K, Rascol O, Stacy MA, Nutt JG, Tanner CM, Urkowitz A, Jaglin JA, Ge S.
    Mov Disord. 2013
    2013 Mar
    28(3):341-6. doi: 10.1002/mds.25321. Epub 2013 Feb 6.
  7. Assessing bradykinesia in parkinsonian disorders.
    Pal G, Goetz CG.
    Front Neurol. 2013
    2013 Jun 3
    4:54. doi: 10.3389/fneur.2013.00054. Print 2013.
  8. Dissociations among daytime sleepiness, nighttime sleep, and cognitive status in Parkinson's disease.
    Goldman JG, Ghode RA, Ouyang B, Bernard B, Goetz CG, Stebbins GT.
    Parkinsonism Relat Disord. 2013
    2013 Jun 2. doi:pii: S1353-8020(13)00193-4. 10.1016/j.parkreldis.2013.05.006. [Epub ahead of print]
  9. The MDS-UPDRS Part II (motor experiences of daily living) resulted useful for assessment of disability in Parkinson's disease.
    Rodriguez-Blazquez C, Rojo-Abuin JM, Alvarez-Sanchez M, Arakaki T, Bergareche-Yarza A, Chade A, Garretto N, Gershanik O, Kurtis MM, Martinez-Castrillo JC, Mendoza-Rodriguez A, Moore HP, Rodriguez-Violante M, Singer C, Tilley BC, Huang J, Stebbins GT, Goetz CG, Martinez-Martin P.
    Parkinsonism Relat Disord. 2013
    2013 Jun 19. doi:pii: S1353-8020(13)00204-6. 10.1016/j.parkreldis.2013.05.017. [Epub ahead of print]
  10. Dystonia rating scales: Critique and recommendations.
    Albanese A, Sorbo FD, Comella C, Jinnah HA, Mink JW, Post B, Vidailhet M, Volkmann J, Warner TT, Leentjens AF, Martinez-Martin P, Stebbins GT, Goetz CG, Schrag A
    Mov. Disord.
    2013 Jun 15
    28(7):874-83.
  11. Measurement of costs and scales for outcome evaluation in health economic studies of Parkinson's disease.
    Dodel R, Jönsson B, Reese JP, Winter Y, Martinez-Martin P, Holloway R, Sampaio C, Ružicka E, Hawthorne G, Oertel W, Poewe W, Stebbins G, Rascol O, Goetz CG, Schrag A
    Mov. Disord.
    2013 Jul 16
  12. I finally see what you see: Parkinson's disease visual hallucinations captured with functional neuroimaging.
    Goetz CG, Vaughan CL, Goldman JG, Stebbins GT.
    Mov Disord. 2013
    2013 Jul 10. doi: 10.1002/mds.25554. [Epub ahead of print]
  13. Expanded and independent validation of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS).
    Martinez-Martin P, Rodriguez-Blazquez C, Alvarez-Sanchez M, Arakaki T, Bergareche-Yarza A, Chade A, Garretto N, Gershanik O, Kurtis MM, Martinez-Castrillo JC, Mendoza-Rodriguez A, Moore HP, Rodriguez-Violante M, Singer C, Tilley BC, Huang J, Stebbins GT, Goetz CG.
    J Neurol. 2013
    2013 Jan
    260(1):228-36. doi: 10.1007/s00415-012-6624-1. Epub 2012 Aug 5.
  14. How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: Comparison with the unified Parkinson's disease rating scale.
    Stebbins GT, Goetz CG, Burn DJ, Jankovic J, Khoo TK, Tilley BC.
    Mov Disord. 2013
    2013 Feb 13. doi: 10.1002/mds.25383. [Epub ahead of print]
  15. Treating melancholia at home: Theoretical wisdom and grim reality in the career of E.C. Seguin.
    Goetz CG, Harter DH.
    Neurology. 2013
    2013 Apr 30
    80(18):1710-4. doi: 10.1212/WNL.0b013e3182904f55.
  16. Force control deficits in individuals with Parkinson's disease, multiple systems atrophy, and progressive supranuclear palsy.
    Neely KA, Planetta PJ, Prodoehl J, Corcos DM, Comella CL, Goetz CG, Shannon KL, Vaillancourt DE.
    PLoS One. 2013
    2013
    8(3):e58403. doi: 10.1371/journal.pone.0058403. Epub 2013 Mar 11.
  17. Calibration of unified Parkinson's disease rating scale scores to Movement Disorder Society-unified Parkinson's disease rating scale scores.
    Goetz CG, Stebbins GT, Tilley BC.
    Mov Disord. 2012
    2012 Sep 1
    27(10):1239-42. doi: 10.1002/mds.25122. Epub 2012 Aug 6.
  18. Tai chi for patients with Parkinson's disease.
    Corcos DM, Comella CL, Goetz CG.
    N Engl J Med. 2012
    2012 May 3
    366(18):1737-8; author reply 1738. doi: 10.1056/NEJMc1202921#SA2. No abstract available.
  19. Entorhinal cortex atrophy differentiates Parkinson's disease patients with and without dementia.
    Goldman JG, Stebbins GT, Bernard B, Stoub TR, Goetz CG, deToledo-Morrell L.
    Mov Disord. 2012
    2012 May
    27(6):727-34. doi: 10.1002/mds.24938. Epub 2012 Mar 12.
  20. Subject-investigator reproducibility of the Unified Parkinson's Disease Rating Scale.
    Seidel SE, Tilley BC, Huang P, Palesch YY, Bergmann KJ, Goetz CG, Swearingen CJ.
    Parkinsonism Relat Disord. 2012
    2012 Mar
    18(3):230-3. doi: 10.1016/j.parkreldis.2011.10.006. Epub 2011 Oct 21.
  21. Validation of the Italian version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale.
    Antonini A, Abbruzzese G, Ferini-Strambi L, Tilley B, Huang J, Stebbins GT, Goetz CG, Barone P; MDS-UPDRS Italian Validation Study Group, Bandettini di Poggio M, Fabbrini G, Di Stasio F, Tinazzi M, Bovi T, Ramat S, Meoni S, Pezzoli G, Canesi M, Martinelli P, Maria Scaglione CL, Rossi A, Tambasco N, et al.
    Neurol Sci. 2012
    2012 Jun 8. [Epub ahead of print]
  22. Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations.
    Galpern WR, Corrigan-Curay J, Lang AE, Kahn J, Tagle D, Barker RA, Freeman TB, Goetz CG, Kieburtz K, Kim SY, Piantadosi S, Comstock Rick A, Federoff HJ.
    Lancet Neurol. 2012
    2012 Jul
    11(7):643-50. doi: 10.1016/S1474-4422(12)70064-9.
  23. Dopamine dysregulation syndrome item from the MDS-UPDRS.
    Goetz CG, Tilley BC, Stebbins GT.
    Mov Disord. 2012
    2012 Jan
    27(1):166. doi: 10.1002/mds.23910. Epub 2011 Oct 24. No abstract available.
  24. Clinical differences among mild cognitive impairment subtypes in Parkinson's disease.
    Goldman JG, Weis H, Stebbins G, Bernard B, Goetz CG.
    Mov Disord. 2012
    2012 Aug
    27(9):1129-36. doi: 10.1002/mds.25062. Epub 2012 Jul 6.
  25. Vibration Therapy for Parkinson's Disease: Charcot's Studies Revisited.
    Kapur SS, Stebbins GT, Goetz CG
    J Parkinsons Dis
    2012
    2(1):23-7.
  26. Validation of the MDS-UPDRS Part I for nonmotor symptoms in Parkinson's disease.
    Gallagher DA, Goetz CG, Stebbins G, Lees AJ, Schrag A.
    Mov Disord.
    2011 Sep 13
    doi: 10.1002/mds.23939
  27. Temporal stability of the Unified Dyskinesia Rating Scale.
    Goetz CG, Stebbins GT, Theeuwes A, Stocchi F, Ferreira JJ, van de Witte S, Bronzova J.
    Mov Disord.
    2011 Sep 13
    doi: 10.1002/mds.23931
  28. An update expert opinion on management and research strategies in Parkinson's disease psychosis.
    Goldman JG, Vaughan CL, Goetz CG.
    Expert Opin Pharmacother.
    2011 Sep
    12(13):2009-24
  29. The history of Parkinson's disease: early clinical descriptions and neurological therapies.
    Goetz CG.
    Cold Spring Harb Perspect Med. 2011
    2011 Sep
    1(1):a008862. doi: 10.1101/cshperspect.a008862.
  30. The Movement Disorders task force review of dysautonomia rating scales in Parkinson's disease with regard to symptoms of orthostatic hypotension.
    Pavy-Le Traon A, Amarenco G, Duerr S, Kaufmann H, Lahrmann H, Shaftman SR, Tison F, Wenning GK, Goetz CG, Poewe W, Sampaio C, Schrag A, Stebbins GT, Rascol O.
    Mov Disord.
    2011 Sep
    26(11):1985-92. doi: 10.1002/mds.23742
  31. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease.
    Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, Hametner EM, Poewe W, Rascol O, Goetz CG, Sampaio C.
    Mov Disord. 2011
    2011 Oct
    26 Suppl 3:S42-80. doi: 10.1002/mds.23884. Review.
  32. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease.
    Fox SH, Katzenschlager R, Lim SY, Ravina B, Seppi K, Coelho M, Poewe W, Rascol O, Goetz CG, Sampaio C.
    Mov Disord. 2011
    2011 Oct
    26 Suppl 3:S2-41. doi: 10.1002/mds.23829. Review.
  33. Priorities in Parkinson's disease research.
    Meissner WG, Frasier M, Gasser T, Goetz CG, Lozano A, Piccini P, Obeso JA, Rascol O, Schapira A, Voon V, Weiner DM, Tison F, Bezard E.
    Nat Rev Drug Discov.
    2011 May
    10(5):377-93
  34. The Movement Disorder Society and Movement Disorders: a modern history.
    Goetz CG, McGhiey A.
    Mov Disord.
    2011 May
    26(6):939-46. doi: 10.1002/mds.23689
  35. Health-related quality-of-life scales in Parkinson's disease: Critique and recommendations.
    Martinez-Martin P, Jeukens-Visser M, Lyons KE, Rodriguez-Blazquez C, Selai C, Siderowf A, Welsh M, Poewe W, Rascol O, Sampaio C, Stebbins GT, Goetz CG, Schrag A.
    Mov Disord.
    2011 Jul 6
    doi: 10.1002/mds.23834
  36. Wearing-off scales in Parkinson's disease: Critique and recommendations.
    Antonini A, Martinez-Martin P, Chaudhuri RK, Merello M, Hauser R, Katzenschlager R, Odin P, Stacy M, Stocchi F, Poewe W, Rascol O, Sampaio C, Schrag A, Stebbins GT, Goetz CG.
    Mov Disord.
    2011 Jul 20
    doi: 10.1002/mds.23875
  37. Visual plus nonvisual hallucinations in Parkinson's disease: Development and evolution over 10 years.
    Goetz CG, Stebbins GT, Ouyang B.
    Mov Disord.
    2011 Jul 13
    doi: 10.1002/mds.23835
  38. Clinical validation of Movement Disorder Society-recommended diagnostic criteria for Parkinson's disease with dementia.
    Barton B, Grabli D, Bernard B, Czernecki V, Goldman JG, Stebbins G, Dubois B, Goetz CG.
    Mov Disord.
    2011 Dec 9
    doi: 10.1002/mds.24059
  39. Racial differences may influence the role of cholecystokinin polymorphisms in Parkinson's disease hallucinations.
    Goldman JG, Marr D, Zhou L, Ouyang B, Leurgans SE, Berry-Kravis E, Goetz CG.
    Mov Disord.
    2011 Aug 1
    26(9):1781-2. doi: 10.1002/mds.23655
  40. Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease
    Schwid SR, Bausch J, Oakes D, Schuchter L, Tanner C, Forrest M, Lang AE, Shoulson I; PSG PRECEPT Investigators, Shoulson I, Hyson C, Oakes D, Flagg E, Rudolph A, Kieburtz K, Lang A, Fahn S, Gauger L, Goetz C
    Mov Disord
    2010 Sep 15
    25(12):1801-8
  41. Hallucinations and sleep disorders in PD: ten-year prospective longitudinal study
    Goetz CG, Ouyang B, Negron A, Stebbins GT
    Neurology
    2010 Nov 16
    75(20):1773-9
  42. Shaking up the Salpetriere: Jean-Martin Charcot and mercury-induced tremor
    Goetz CG
    Neurology
    2010 May 25
    74(21):1739-42
  43. Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease
    Friedman JH, Alves G, Hagell P, Marinus J, Marsh L, Martinez-Martin P, Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins G, Schrag A
    Mov Disord
    2010 May 15
    25(7):805-22
  44. Missing pieces in the Parkinson's disease puzzle
    Obeso JA, Rodriguez-Oroz MC, Goetz CG, Marin C, Kordower JH, Rodriguez M, Hirsch EC, Farrer M, Schapira AH, Halliday G
    Nat Med
    2010 Jun
    16(6):653-61
  45. Task force report on scales to assess dyskinesia in Parkinson's disease: critique and recommendations
    Colosimo C, Martínez-Martín P, Fabbrini G, Hauser RA, Merello M, Miyasaki J, Poewe W, Sampaio C, Rascol O, Stebbins GT, Schrag A, Goetz CG
    Mov Disord
    2010 Jul 15
    25(9):1131-42
  46. Teaching program for the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale: (MDS-UPDRS)
    Goetz CG, Stebbins GT, Chmura TA, Fahn S, Poewe W, Tanner CM
    Mov Disord
    2010 Jul 15
    25(9):1190-4
  47. Fibroblast phenotype in male carriers of FMR1 premutation alleles
    Garcia-Arocena D, Yang JE, Brouwer JR, Tassone F, Iwahashi C, Berry-Kravis EM, Goetz CG, Sumis AM, Zhou L, Nguyen DV, Campos L, Howell E, Ludwig A, Greco C, Willemsen R, Hagerman RJ, Hagerman PJ
    Hum Mol Genet
    2010 Jan 15
    19(2):299-312
  48. Scales to assess sleep impairment in Parkinson's disease: critique and recommendations
    Högl B, Arnulf I, Comella C, Ferreira J, Iranzo A, Tilley B, Trenkwalder C, Poewe W, Rascol O, Sampaio C, Stebbins GT, Schrag A, Goetz CG
    Mov Disord
    2010 Dec 15
    25(16):2704-16
  49. A 12-year population-based study of psychosis in Parkinson disease
    Forsaa EB, Larsen JP, Wentzel-Larsen T, Goetz CG, Stebbins GT, Aarsland D, Alves G
    Arch Neurol
    2010 Aug
    67(8):996-1001
  50. Association between antipsychotics and body mass index when treating patients with tics
    Kompoliti K, Stebbins GT, Goetz CG, Fan W
    J Child Adolesc Psychopharmacol
    2010 Aug
    20(4):277-81
  51. Chapter 15: Jean-Martin Charcot and the anatomo-clinical method of neurology
    Goetz CG
    Handb Clin Neurol
    2010
    95:203-12
  52. New developments in depression, anxiety, compulsiveness, and hallucinations in Parkinson's disease
    Goetz CG
    Mov Disord
    2010
    25 Suppl 1:S104-9
  53. Using global statistical tests in long-term Parkinson's disease clinical trials
    Huang P, Goetz CG, Woolson RF, Tilley B, Kerr D, Palesch Y, Elm J, Ravina B, Bergmann KJ, Kieburtz K; Parkinson Study Group
    Mov Disord
    2009 Sep 15
    24(12):1732-9
  54. A longitudinal program for biomarker development in Parkinson's disease: a feasibility study
    Ravina B, Tanner C, Dieuliis D, Eberly S, Flagg E, Galpern WR, Fahn S, Goetz CG, Grate S, Kurlan R, Lang AE, Marek K, Kieburtz K, Oakes D, Elliott R, Shoulson I; Parkinson Study Group LABS-PD Investigators
    Mov Disord
    2009 Oct 30
    24(14):2081-90
  55. Charcot and Pasteur: intersecting orbits in fin de siècle French medicine
    Goetz CG, Harter DH
    J Hist Neurosci
    2009 Oct
    18(4):378-86
  56. Determinants of quality of life in children with Gilles de la Tourette syndrome
    Bernard BA, Stebbins GT, Siegel S, Schultz TM, Hays C, Morrissey MJ, Leurgans S, Goetz CG
    Mov Disord
    2009 May 15
    24(7):1070-3
  57. Testing objective measures of motor impairment in early Parkinson's disease: Feasibility study of an at-home testing device
    Goetz CG, Stebbins GT, Wolff D, DeLeeuw W, Bronte-Stewart H, Elble R, Hallett M, Nutt J, Ramig L, Sanger T, Wu AD, Kraus PH, Blasucci LM, Shamim EA, Sethi KD, Spielman J, Kubota K, Grove AS, Dishman E, Taylor CB
    Mov Disord
    2009 Mar 15
    24(4):551-6
  58. Hallucinations in Parkinson disease
    Diederich NJ, Fénelon G, Stebbins G, Goetz CG
    Nat Rev Neurol
    2009 Jun
    5(6):331-42
  59. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients
    Hinson VK, Goetz CG, Leurgans S, Fan W, Nguyen T, Hsu A
    Clin Neuropharmacol
    2009 Jul-Aug
    32(4):189-92
  60. Teaching program for the Unified Dyskinesia Rating Scale
    Goetz CG, Nutt JG, Stebbins GT, Chmura TA
    Mov Disord
    2009 Jul 15
    24(9):1296-8
  61. Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis
    Olanow CW, Gracies JM, Goetz CG, Stoessl AJ, Freeman T, Kordower JH, Godbold J, Obeso JA
    Mov Disord
    2009 Feb 15
    24(3):336-43
  62. Scales to evaluate psychosis in Parkinson's disease
    Goetz CG
    Parkinsonism Relat Disord
    2009 Dec
    15 Suppl 3:S38-41
  63. Jean-Martin Charcot and his vibratory chair for Parkinson disease
    Goetz CG
    Neurology
    2009 Aug 11
    73(6):475-8
  64. Dysautonomia rating scales in Parkinson's disease: sialorrhea, dysphagia, and constipation--critique and recommendations by movement disorders task force on rating scales for Parkinson's disease
    Evatt ML, Chaudhuri KR, Chou KL, Cubo E, Hinson V, Kompoliti K, Yang C, Poewe W, Rascol O, Sampaio C, Stebbins GT, Goetz CG
    Mov Disord
    2009 Apr 15
    24(5):635-46
  65. Movement disorders caused by medical disease
    Barton B, Zauber SE, Goetz CG
    Semin Neurol
    2009 Apr
    29(2):97-110
  66. Anxiety rating scales in Parkinson's disease: critique and recommendations
    Leentjens AF, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, Starkstein SE, Weintraub D, Sampaio C, Poewe W, Rascol O, Stebbins GT, Goetz CG
    Mov Disord
    2008 Oct 30
    23(14):2015-25
  67. Apathy and anhedonia rating scales in Parkinson's disease: critique and recommendations
    Leentjens AF, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, Starkstein SE, Weintraub D, Sampaio C, Poewe W, Rascol O, Stebbins GT, Goetz CG
    Mov Disord
    2008 Oct 30
    23(14):2004-14
  68. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results
    Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, LaPelle N; Movement Disorder Society UPDRS Revision Task Force
    Mov Disord
    2008 Nov 15
    23(15):2129-70
  69. Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies
    Goldman JG, Goetz CG, Brandabur M, Sanfilippo M, Stebbins GT
    Mov Disord
    2008 Nov 15
    23(15):2248-50
  70. Scales to assess psychosis in Parkinson's disease: Critique and recommendations
    Fernandez HH, Aarsland D, Fénelon G, Friedman JH, Marsh L, Tröster AI, Poewe W, Rascol O, Sampaio C, Stebbins GT, Goetz CG
    Mov Disord
    2008 Mar 15
    23(4):484-500
  71. Concerning about the accuracy of data reported
    Goetz CG
    Mov Disord
    2008 Mar 15
    23(4):473; author reply 473
  72. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease
    Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, Shoulson I, Ascherio A; Parkinson Study Group PRECEPT Investigators, Hyson C, Gorbold E, Rudolph A, Kieburtz K, Fahn S, Gauger L, Goetz C, Seibyl J, Forrest M, Ondrasik J
    Arch Neurol
    2008 Jun
    65(6):716-23
  73. Visual hallucinations and symptoms of REM sleep behavior disorder in Parkinsonian tauopathies
    Diederich NJ, Leurgans S, Fan W, Chmura TA, Goetz CG
    Int J Geriatr Psychiatry
    2008 Jun
    23(6):598-603
  74. Evaluating Parkinson's disease patients at home: utility of self-videotaping for objective motor, dyskinesia, and ON-OFF assessments
    Goetz CG, Leurgans S, Hinson VK, Blasucci LM, Zimmerman J, Fan W, Nguyen T, Hsu A
    Mov Disord
    2008 Jul 30
    23(10):1479-82
  75. The Unified Dyskinesia Rating Scale: presentation and clinimetric profile
    Goetz CG, Nutt JG, Stebbins GT
    Mov Disord
    2008 Dec 15
    23(16):2398-403
  76. Comparison of tic characteristics between children and adults
    Cubo E, Chmura T, Goetz CG
    Mov Disord
    2008 Dec 15
    23(16):2407-11
  77. Parkinson's disease dementia: definitions, guidelines, and research perspectives in diagnosis
    Goetz CG, Emre M, Dubois B
    Ann Neurol
    2008 Dec
    64 Suppl 2:S81-92
  78. The placebo treatments in neurosciences: New insights from clinical and neuroimaging studies
    Diederich NJ, Goetz CG
    Neurology
    2008 Aug 26
    71(9):677-84
  79. Antipsychotic medication treatment for mild hallucinations in Parkinson's disease: Positive impact on long-term worsening
    Goetz CG, Fan W, Leurgans S
    Mov Disord
    2008 Aug 15
    23(11):1541-5
  80. Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions
    Goetz CG, Wuu J, McDermott MP, Adler CH, Fahn S, Freed CR, Hauser RA, Olanow WC, Shoulson I, Tandon PK; Parkinson Study Group, Leurgans S
    Mov Disord
    2008 Apr 15
    23(5):690-9
  81. Placebo influences on dyskinesia in Parkinson's disease
    Goetz CG, Laska E, Hicking C, Damier P, Müller T, Nutt J, Warren Olanow C, Rascol O, Russ H
    Mov Disord
    2008 Apr 15
    23(5):700-7
  82. fMRI activation changes during successful episodic memory encoding and recognition in amnestic mild cognitive impairment relative to cognitively healthy older adults
    Trivedi MA, Murphy CM, Goetz C, Shah RC, Gabrieli JD, Whitfield-Gabrieli S, Turner DA, Stebbins GT
    Dement Geriatr Cogn Disord
    2008
    26(2):123-37
  • (If you cannot play the video, you may need to update to the latest version of Adobe Flash Player.)
  • View Transcript

Find a Doctor | Patient & Visitor Services | Health Information | Clinical Services | Events & Classes | News Room | Clinical Trials | Research at Rush
Nursing at Rush | Work at Rush | Giving to Rush | Directions to Rush | Disclaimer | Privacy Statement
For Physicians | For Rush Employees | For Students | Bill Payment Center | Site Map
© Rush University Medical Center
1653 W. Congress Parkway, Chicago, Illinois 60612